Two New “All About Grants” Podcasts: 2018 Appendix Policy Changes, and Why We Encourage You to Submit Your Application Early

NIH’s Office of Extramural Research brings you two new “All About Grants”  podcasts to ring in the new year. In “Why it’s so Important to Submit Applications Early”, Dr. Cathie Cooper, director of the Division of Receipt and Referral in the NIH’s Center for Scientific Review, talks about the importance of submitting application early due to changes in NIH’s policies and application forms for 2018…. Continue reading

Email this to someoneTweet about this on TwitterShare on FacebookShare on LinkedInShare on Google+Pin on PinterestPrint this page

Two Years (or so) of “Open Mike”

Last year, as I reflected on finishing my first full year as NIH Deputy Director for Extramural Research, I noted five themes that reflected most of the content of this blog: applicant behavior, activity, and outcomes; peer review; basic science; biomedical research workforce and training; and scientific rigor, transparency, and research impact. Looking back on 2017, which was certainly a busy and active year, many of these themes continue to be at the forefront, though one in particular, the make-up and future of the biomedical research workforce, has been the center of much debate. …. Continue reading

Email this to someoneTweet about this on TwitterShare on FacebookShare on LinkedInShare on Google+Pin on PinterestPrint this page

Which Funding Opportunity Announcement (FOA) Should I Use if My Human Subject Research Study is Delayed Onset?

The type of FOA you will need depends on whether you anticipate that your delayed onset human subject study will meet the definition of a clinical trial.

If it will, you will need to choose a funding opportunity that explicitly allows clinical trials (it will be designated ‘Clinical Trial Optional’ or ‘Clinical Trial Required’). Be sure to check the ‘Anticipated Clinical Trial’ box when completing your Delayed Onset Study record within the application.

If no clinical trial is involved, you will need to choose a funding opportunity designated as ‘Clinical Trial Optional’ or ‘Clinical Trial Not Allowed.’

When completing your application, follow the SF 424’s Delayed Onset Study instructions …. Continue reading

Email this to someoneTweet about this on TwitterShare on FacebookShare on LinkedInShare on Google+Pin on PinterestPrint this page

New Electronic Submission Requirement for Diversity Supplements

The funds provided in response to Diversity Supplement requests are used to improve the diversity of the biomedical research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from groups that have been shown to be underrepresented in health-related research. Currently, NIH does not require that diversity supplements be submitted electronically, which poses a challenge to NIH staff when trying to identify and track diversity supplement awardees and their subsequent research careers. Effective January 25, 2018, all single and multi-project diversity supplement requests MUST be submitted electronically …. Continue reading

Email this to someoneTweet about this on TwitterShare on FacebookShare on LinkedInShare on Google+Pin on PinterestPrint this page

Assuring the Integrity of Peer Review

Eight months ago, CSR Director Dr. Richard Nakamura and I posted a blog on “A Reminder of Your Roles as Applicants and Reviewers in Maintaining the Confidentiality of Peer Review.” We asked you to imagine a scenario: you are a reviewer for an upcoming panel meeting, and shortly before the meeting an investigator associated with an application communicates with you, asking for a favorable review in exchange for an academic favor. We asked what you would do – accept the offer, ignore it, or report it?

We used the blog as an opportunity to remind all of us how important it is that we all do our utmost to assure the integrity of peer review. …. Continue reading

Email this to someoneTweet about this on TwitterShare on FacebookShare on LinkedInShare on Google+Pin on PinterestPrint this page

The Importance of Timely Grant Closeout

At any given time, NIH staff are monitoring nearly 50,000 active grant awards. This monitoring happens throughout the grant life cycle, including once the award is over. Just as we strive to award meritorious grants as quickly as we can, it is equally important for us to ensure grant awards are taken off the books in a timely manner. A grant that slips past its closeout due date is costly and time consuming. Continue reading

Email this to someoneTweet about this on TwitterShare on FacebookShare on LinkedInShare on Google+Pin on PinterestPrint this page

NIH Single IRB Policy Reminder

As we approach the implementation date for NIH’s Policy on the Use of a Single Institutional Review Board (Single IRB) for Multi-Site Research, we would like to remind you of the resources available for understanding this policy. 

The policy affects multi-site studies involving non-exempt human subjects research funded by NIH, and applies to grant applications with due dates on or after January 25, 2018 and R&D contracts in response to solicitations issued on or after January 25, 2018.

We encourage you to familiarize yourself with the single IRB plan, considerations in the selection of the sIRB, costs, exceptions to the policy, and where you should include this information as part of your grant application or contract proposal.

Visit the following resources to learn more: …. Continue reading

Email this to someoneTweet about this on TwitterShare on FacebookShare on LinkedInShare on Google+Pin on PinterestPrint this page